SCHEMBL10086149

SCHEMBL10086149

Cc1ccc2[nH]c(C)c(C(=O)O)c(=O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 5/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
MAPT P10636 4/20 0.55
GAA P10253 1/20 0.55
NPC1 O15118 4/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 5/20 0.49
HTT P42858 2/20 0.49
GFER P55789 1/20 0.49
THRB P10828 1/20 0.47
APEX1 P27695 1/20 0.47
MITF O75030 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18932673 0.88 ALDH1A1 (0.59) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL17792392 0.83 NR4A2 (0.57) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL10086148 0.81 GAA (0.63) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL10513594 0.80 RAB9A (0.65) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL10915060 0.80 ALDH1A1 (0.63) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL27831437 0.78 ALDH1A1 (0.55) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL11066329 0.78 ALDH1A1 (0.50) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL9724156 0.78 HSD17B10 (0.65) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL27469947 0.77 MEN1 (0.60) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL13933160 0.77 NPC1 (0.81) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 HSD17B10 4071/4885SMN1; SMN2 3062/4885KDM4E 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.